Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow diagram of study selection. Including identification, screening, eligibility, and inclusion of studies in the meta-analysis. TKI: Tyrosine kinase inhibitor.

Figure 2 Methodological quality assessment of included studies using the Methodological Index for Non-Randomized Studies tool.

Figure 3 Forest plots of primary outcomes following tyrosine kinase inhibitor therapy after progression on atezolizumab-bevacizumab. A: Overall survival; B: Progression-free survival. REML: Restricted maximum likelihood; CI: Confidence interval.

Figure 4 Forest plots of clinical response outcomes according to Response Evaluation Criteria in Solid Tumors version 1. 1. A: Complete response; B: Partial response; C: Stable disease; D: Progressive disease; E: Objective response rate; F: Disease control rate; G: Not evaluable. REML: Restricted maximum likelihood; CI: Confidence interval.

Figure 5 Forest plots of clinical response outcomes according to modified Response Evaluation Criteria in Solid Tumors (modified Response Evaluation Criteria in Solid Tumors). A: Complete response; B: Partial response; C: Stable disease; D: Progressive disease; E: Objective response rate; F: Disease control rate; G: Not evaluable. REML: Restricted maximum likelihood; CI: Confidence interval.